CA2370351A1
(en)
*
|
1999-04-22 |
2000-11-02 |
Unilever Plc |
Inhibition of viral infection using monovalent antigen-binding proteins
|
WO2001007555A1
(en)
|
1999-07-27 |
2001-02-01 |
Unilever N.V. |
Bleaching detergent compositions
|
PT1233987E
(pt)
*
|
1999-11-29 |
2009-12-28 |
Bac Ip B V |
Imobilização de moléculas de ligação ao antigénio de um domínio
|
CA2394722C
(en)
|
1999-12-22 |
2011-06-28 |
Unilever Plc |
Two-step process for treating fabric via multispecific binding molecules
|
BR0016657B1
(pt)
|
1999-12-22 |
2010-12-14 |
|
mÉtodo para liberar um agente de benefÍcio a uma Área selecionada de um tecido para exercer uma atividade prÉ-determinada, e, dispositivo para uso no mesmo.
|
EP1240298B1
(en)
|
1999-12-22 |
2007-10-31 |
Unilever N.V. |
Detergent compositions comprising benefit agents
|
WO2001046364A2
(en)
|
1999-12-22 |
2001-06-28 |
Unilever Plc |
Method of delivering a benefit agent
|
WO2001048135A1
(en)
*
|
1999-12-23 |
2001-07-05 |
Unilever N.V. |
Bleaching detergent compositions
|
AU2001247616B2
(en)
*
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
US20060073141A1
(en)
*
|
2001-06-28 |
2006-04-06 |
Domantis Limited |
Compositions and methods for treating inflammatory disorders
|
JP2005289809A
(ja)
*
|
2001-10-24 |
2005-10-20 |
Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) |
突然変異重鎖抗体
|
WO2003054016A2
(en)
*
|
2001-12-21 |
2003-07-03 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Method for cloning of variable domain sequences
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
CA2492092A1
(en)
|
2002-06-28 |
2004-01-08 |
Greg Winter |
Immunoglobin single variant antigen-binding domains and dual-specific constructs
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
ES2368733T3
(es)
|
2002-07-18 |
2011-11-21 |
Merus B.V. |
Producción recombinante de mezclas de anticuerpos.
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
ATE512364T1
(de)
*
|
2002-08-07 |
2011-06-15 |
Ablynx Nv |
Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
|
BRPI0316092B8
(pt)
*
|
2002-11-08 |
2021-05-25 |
Ablynx Nv |
anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
|
US20060228355A1
(en)
*
|
2003-11-07 |
2006-10-12 |
Toon Laeremans |
Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
PT2316852E
(pt)
*
|
2002-11-08 |
2014-06-23 |
Ablynx Nv |
Anticorpos de domínio único estáveis
|
US20100003253A1
(en)
*
|
2002-11-08 |
2010-01-07 |
Ablynx N.V. |
Single domain antibodies directed against epidermal growth factor receptor and uses therefor
|
US20060034833A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Els Beirnaert |
Single domain antibodies directed against interferron-gamma and uses therefor
|
US20060034845A1
(en)
*
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
EP3299393A1
(en)
*
|
2002-11-08 |
2018-03-28 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
US6974860B2
(en)
|
2002-12-30 |
2005-12-13 |
Kimberly-Clark Worldwide, Inc. |
Target recognizing binding agents
|
US9028816B2
(en)
|
2003-01-10 |
2015-05-12 |
Ablynx N.V. |
Polypeptides and polypeptide constructs comprising single domain antibodies directed against von Willebrand factor
|
EP1639009B1
(en)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
NZ548828A
(en)
*
|
2004-01-20 |
2009-07-31 |
Merus B V |
Mixtures of binding proteins
|
EP1733233B1
(en)
*
|
2004-03-30 |
2012-12-12 |
GE Healthcare Bio-Sciences Corp. |
Lateral flow format, materials and methods
|
WO2005113604A2
(en)
*
|
2004-05-14 |
2005-12-01 |
Hematech, Llc |
Methods for immunoglobulin purification
|
US7563443B2
(en)
|
2004-09-17 |
2009-07-21 |
Domantis Limited |
Monovalent anti-CD40L antibody polypeptides and compositions thereof
|
RU2401842C2
(ru)
|
2004-10-08 |
2010-10-20 |
Домантис Лимитед |
Антагонисты и способы их применения
|
CN101072794B
(zh)
*
|
2004-12-02 |
2012-07-04 |
贝克知产公司 |
亲和纯化方法
|
FR2879605B1
(fr)
|
2004-12-16 |
2008-10-17 |
Centre Nat Rech Scient Cnrse |
Production de formats d'anticorps et applications immunologiques de ces formats
|
CA2593328C
(en)
|
2005-01-14 |
2018-02-06 |
Ablynx N.V. |
Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between von willebrand factor (vwf) and platelets
|
EP1888641B1
(en)
|
2005-05-18 |
2011-12-14 |
Ablynx N.V. |
Serum albumin binding proteins
|
JP4986997B2
(ja)
*
|
2005-05-20 |
2012-07-25 |
アブリンクス エン.ヴェー. |
凝集媒介障害の治療における改良ナノボディ(商標)
|
DE102005023617A1
(de)
*
|
2005-05-21 |
2006-11-23 |
Aspre Ag |
Verfahren zum Mischen von Farben in einem Display
|
JP2009508521A
(ja)
*
|
2005-09-23 |
2009-03-05 |
アカデミッシュ ジーケンハイス レイデン |
タンパク凝集に関連する疾患の診断予防及び治療のためのvhh
|
US20070269422A1
(en)
*
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
GB0621513D0
(en)
|
2006-10-30 |
2006-12-06 |
Domantis Ltd |
Novel polypeptides and uses thereof
|
AU2007336242B2
(en)
|
2006-12-19 |
2012-08-30 |
Ablynx N.V. |
Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
|
CA2672965C
(en)
|
2006-12-19 |
2018-02-06 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
CA2700714C
(en)
|
2007-09-26 |
2018-09-11 |
Ucb Pharma S.A. |
Dual specificity antibody fusions
|
US20110158996A1
(en)
*
|
2008-03-21 |
2011-06-30 |
Ablynx N.V. |
Von willebrand factor specific binders and methods of use therefor
|
WO2009124931A2
(en)
|
2008-04-07 |
2009-10-15 |
Ablynx Nv |
Amino acid sequences directed against the notch pathways and uses thereof
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
BRPI0913406A2
(pt)
|
2008-06-03 |
2018-01-09 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e usos das mesmas
|
JP5723769B2
(ja)
|
2008-06-03 |
2015-05-27 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
JP5674654B2
(ja)
|
2008-07-08 |
2015-02-25 |
アッヴィ・インコーポレイテッド |
プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
JP6063122B2
(ja)
*
|
2008-09-26 |
2017-01-18 |
ユセベ ファルマ ソシエテ アノニム |
生物学的産物
|
RU2481824C2
(ru)
|
2008-10-29 |
2013-05-20 |
Аблинкс Н.В |
Препараты однодоменных антигенсвязывающих молекул
|
WO2010056550A1
(en)
|
2008-10-29 |
2010-05-20 |
Wyeth Llc |
Methods for purification of single domain antigen binding molecules
|
EP3470425A3
(en)
|
2008-12-19 |
2019-07-17 |
Ablynx N.V. |
Immunoglobulins against cell-associatd antigens such as p2x7
|
ES2701649T3
(es)
|
2009-01-14 |
2019-02-25 |
Ablynx Nv |
Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos
|
EP2403873A1
(en)
|
2009-03-05 |
2012-01-11 |
Ablynx N.V. |
Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
AU2010243551B2
(en)
|
2009-04-30 |
2015-03-26 |
Ablynx Nv |
Method for the production of domain antibodies
|
HUE051430T2
(hu)
|
2009-07-10 |
2021-03-01 |
Ablynx Nv |
Eljárás variábilis domének elõállítására
|
US8586714B2
(en)
|
2009-09-01 |
2013-11-19 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP3438126B1
(en)
|
2009-09-03 |
2020-08-19 |
Ablynx N.V. |
Stable formulations of polypeptides and uses thereof
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
WO2011045079A1
(en)
|
2009-10-15 |
2011-04-21 |
Intercell Ag |
Hepatitis b virus specific human antibodies
|
JPWO2011046218A1
(ja)
*
|
2009-10-16 |
2013-03-07 |
株式会社カネカ |
抗体を生産するハンゼヌラ・ポリモルファ、それを用いた抗体の生産方法、およびそれにより得られる抗体
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
EP3309176A1
(en)
|
2009-12-14 |
2018-04-18 |
Ablynx N.V. |
Immunoglobulin single variable domain antibodies against ox40l, constructs and therapeutic use
|
WO2011083141A2
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Method for generation of immunoglobulin sequences by using lipoprotein particles
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
US20130012916A1
(en)
|
2010-02-11 |
2013-01-10 |
Glide Pharmaceutical Technologies Limited |
Delivery of immunoglobulin variable domains and constructs thereof
|
ES2931330T3
(es)
|
2010-02-11 |
2022-12-28 |
Ablynx Nv |
Métodos y composiciones para la preparación de aerosoles
|
EP2571901B1
(en)
|
2010-05-20 |
2019-01-02 |
Ablynx N.V. |
Biological materials related to her3
|
WO2011161263A1
(en)
|
2010-06-25 |
2011-12-29 |
Ablynx Nv |
Pharmaceutical compositions for cutaneous administration
|
KR20130100118A
(ko)
|
2010-08-03 |
2013-09-09 |
아비에 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
RU2013113225A
(ru)
|
2010-08-26 |
2014-10-10 |
Эббви Инк. |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
WO2012042026A1
(en)
|
2010-09-30 |
2012-04-05 |
Ablynx Nv |
Biological materials related to c-met
|
US20130261288A1
(en)
|
2010-10-29 |
2013-10-03 |
Ablynx N.V. |
Method for the production of immunoglobulin single variable domains
|
CA2817132A1
(en)
|
2010-11-08 |
2012-05-18 |
Novartis Ag |
Cxcr2 binding polypeptides
|
DK2691415T3
(da)
|
2011-03-28 |
2018-10-29 |
Ablynx Nv |
Fremgangsmåde til fremstilling af faste formuleringer, der omfatter variable enkeltdomæner af immunoglobulin
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
WO2012152823A1
(en)
|
2011-05-09 |
2012-11-15 |
Ablynx Nv |
Method for the production of immunoglobulin single variable domains
|
PT2723771T
(pt)
|
2011-06-23 |
2019-12-11 |
Ablynx Nv |
Proteínas de ligação à albumina sérica
|
EP2747782B1
(en)
|
2011-09-23 |
2018-01-17 |
Ablynx NV |
Prolonged inhibition of interleukin-6 mediated signaling
|
JP6219287B2
(ja)
|
2011-09-30 |
2017-10-25 |
アブリンクス エン.ヴェー. |
c−Metに関連する生物学的物質
|
RU2739792C1
(ru)
|
2011-11-30 |
2020-12-28 |
Чугаи Сейяку Кабусики Кайся |
Содержащий лекарственное средство переносчик в клетку для формирования иммунного комплекса
|
BR112014015851A2
(pt)
|
2011-12-30 |
2019-09-24 |
Abbvie Inc |
proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
|
EA035344B1
(ru)
|
2012-04-20 |
2020-05-29 |
Мерюс Н.В. |
Способ получения двух антител из одной клетки-хозяина
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
SG10202006507XA
(en)
|
2012-05-30 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Target-tissue-specific antigen-binding molecule
|
US11339208B1
(en)
|
2012-05-31 |
2022-05-24 |
United States Of America As Represented By The Secretary Of The Air Force |
Camelidae single-domain antibodies against Yersinia pestis and methods of use
|
UY35110A
(es)
|
2012-11-01 |
2014-05-30 |
Abbvie Inc |
Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
|
US9062108B2
(en)
|
2013-03-15 |
2015-06-23 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-1 and/or IL-17
|
BR112015024587B1
(pt)
|
2013-04-02 |
2022-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
Variante de região fc de igg1 humana, polipeptídeo compreendendo a mesma, seu método de produção e composição farmacêutica
|
NL1040254C2
(en)
|
2013-05-17 |
2014-11-24 |
Ablynx Nv |
Stable formulations of immunoglobulin single variable domains and uses thereof.
|
JP7060317B2
(ja)
|
2013-12-04 |
2022-04-26 |
中外製薬株式会社 |
化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
MX2016011993A
(es)
|
2014-03-14 |
2016-12-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas.
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
US10851149B2
(en)
|
2014-08-14 |
2020-12-01 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using GFR α-4 chimeric antigen receptor
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
EA201790624A1
(ru)
|
2014-09-17 |
2017-08-31 |
Новартис Аг |
Нацеливание цитотоксических клеток с химерными рецепторами для адоптивной иммунотерапии
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
EP3233910B1
(en)
|
2014-12-19 |
2019-12-11 |
Ablynx N.V. |
Cysteine linked nanobody dimers
|
DK4089113T3
(da)
|
2015-03-31 |
2024-02-05 |
Sorriso Pharmaceuticals Inc |
Polypeptider
|
CN107646039B
(zh)
|
2015-04-02 |
2022-04-15 |
埃博灵克斯股份有限公司 |
具有有效抗hiv活性的双特异性cxcr4-cd4多肽
|
SI3280729T1
(sl)
|
2015-04-08 |
2022-09-30 |
Novartis Ag |
Terapije CD20, terapije CD22 in kombinacija terapij s celico, ki izraža himerni antigenski receptor CD19 (CAR)
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
AU2016260909B2
(en)
|
2015-05-13 |
2019-08-22 |
Ablynx N.V. |
T cell recruiting polypeptides based on CD3 reactivity
|
SI3294768T1
(sl)
|
2015-05-13 |
2019-11-29 |
Ablynx Nv |
Polipeptidi, ki rekrutirajo celice T, na osnovi reaktivnosti TCR alfa/beta
|
BR112017024899A2
(pt)
|
2015-05-21 |
2018-11-13 |
Harpoon Therapeutics, Inc. |
proteínas de ligação trispecíficas e métodos de uso.
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
EP4378957A3
(en)
|
2015-07-29 |
2024-08-07 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
NO2768984T3
(da)
|
2015-11-12 |
2018-06-09 |
|
|
JP7195142B2
(ja)
|
2015-11-13 |
2022-12-23 |
アブリンクス エン.ヴェー. |
改善された血清アルブミン結合性免疫グロブリン可変ドメイン
|
TWI754621B
(zh)
|
2015-11-18 |
2022-02-11 |
美商默沙東藥廠 |
Pd1及/或 lag3結合劑
|
UA125337C2
(uk)
|
2015-11-18 |
2022-02-23 |
Мерк Шарп І Доум Корп. |
Ctla4-зв'язувальні речовини
|
CN114605530A
(zh)
|
2015-11-18 |
2022-06-10 |
埃博灵克斯股份有限公司 |
改进的血清白蛋白结合剂
|
TN2018000180A1
(en)
|
2015-11-27 |
2019-10-04 |
Ablynx Nv |
Polypeptides inhibiting cd40l
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
AU2016369623A1
(en)
|
2015-12-17 |
2018-06-28 |
Novartis Ag |
Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
|
US20210198368A1
(en)
|
2016-01-21 |
2021-07-01 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
CA3016287A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
KR20220133318A
(ko)
|
2016-04-15 |
2022-10-04 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
WO2017191108A1
(en)
|
2016-05-02 |
2017-11-09 |
Ablynx Nv |
Treatment of rsv infection
|
CN109641047A
(zh)
|
2016-05-20 |
2019-04-16 |
哈普恩治疗公司 |
单结构域血清白蛋白结合蛋白质
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
EA201892693A1
(ru)
|
2016-05-20 |
2019-04-30 |
Харпун Терапьютикс, Инк. |
Белки, содержащие одноцепочечный вариабельный фрагмент, связывающийся с cd3
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
WO2018007442A1
(en)
|
2016-07-06 |
2018-01-11 |
Ablynx N.V. |
Treatment of il-6r related diseases
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
CA3032581A1
(en)
|
2016-08-01 |
2018-02-08 |
Novartis Ag |
Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
|
WO2018029182A1
(en)
|
2016-08-08 |
2018-02-15 |
Ablynx N.V. |
Il-6r single variable domain antibodies for treatment of il-6r related diseases
|
EP3512880A1
(en)
|
2016-09-15 |
2019-07-24 |
Ablynx NV |
Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
|
WO2018060453A1
(en)
|
2016-09-30 |
2018-04-05 |
Vhsquared Limited |
Compositions
|
AR110676A1
(es)
|
2016-10-07 |
2019-04-24 |
Novartis Ag |
Tratamiento del cáncer utilizando receptores de antígenos quiméricos
|
US11840569B2
(en)
|
2016-11-16 |
2023-12-12 |
Ablynx N.V. |
T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
|
US10844134B2
(en)
|
2016-11-23 |
2020-11-24 |
Harpoon Therapeutics, Inc. |
PSMA targeting trispecific proteins and methods of use
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス,インク. |
前立腺特異的膜抗原結合タンパク質
|
WO2018099968A1
(en)
|
2016-11-29 |
2018-06-07 |
Ablynx N.V. |
Treatment of infection by respiratory syncytial virus (rsv)
|
RU2022101604A
(ru)
|
2016-12-07 |
2022-03-29 |
Аблинкс Нв |
Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином
|
SG10202108972RA
(en)
|
2017-01-17 |
2021-09-29 |
Ablynx Nv |
Improved serum albumin binders
|
BR112019014600A2
(pt)
|
2017-01-17 |
2020-02-18 |
Ablynx N.V. |
Ligantes de albumina sérica melhorados
|
WO2018140725A1
(en)
|
2017-01-26 |
2018-08-02 |
Novartis Ag |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
WO2018160754A2
(en)
|
2017-02-28 |
2018-09-07 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
CN113896792A
(zh)
*
|
2017-05-12 |
2022-01-07 |
哈普恩治疗公司 |
间皮素结合蛋白质
|
US11813307B2
(en)
|
2017-06-02 |
2023-11-14 |
Merck Patent Gmbh |
Polypeptides binding ADAMTS5, MMP13 and aggrecan
|
CA3065630A1
(en)
|
2017-06-02 |
2018-12-06 |
Ablynx Nv |
Aggrecan binding immunoglobulins
|
CN111032695B
(zh)
|
2017-06-02 |
2024-06-25 |
默克专利股份有限公司 |
结合adamts的免疫球蛋白
|
EP3630178A1
(en)
|
2017-06-02 |
2020-04-08 |
Merck Patent GmbH |
Mmp13 binding immunoglobulins
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
WO2019006007A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
POSOLOGICAL REGIMES FOR ANTI-TIM3 ANTIBODIES AND USES THEREOF
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
BR112019028269A2
(pt)
|
2017-07-11 |
2020-07-14 |
Alexion Pharmaceuticals, Inc. |
polipeptídeos que se ligam ao componente c5 do complemento ou à albumina sérica e suas proteínas de fusão
|
US11155607B2
(en)
|
2017-07-19 |
2021-10-26 |
Vib Vzw |
Serum albumin binding agents
|
WO2019018730A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
DOSAGE REGIMES FOR ANTI-LAG3 ANTIBODIES AND USES THEREOF
|
CR20200196A
(es)
|
2017-10-13 |
2020-06-05 |
Harpoon Therapeutics Inc |
Proteínas trispecìficas y mètodos de uso
|
EA202090739A1
(ru)
|
2017-10-13 |
2020-09-07 |
Харпун Терапьютикс, Инк. |
Белки, связывающие антиген созревания в-клеток
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
EP3710053A1
(en)
|
2017-11-16 |
2020-09-23 |
Novartis AG |
Combination therapies
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
JP2021506310A
(ja)
|
2017-12-22 |
2021-02-22 |
アルゲン−エックス ビーブイビーエー |
二重特異性抗原結合コンストラクト
|
CA3090249A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
TW202016139A
(zh)
|
2018-06-13 |
2020-05-01 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
MA52969A
(fr)
|
2018-06-19 |
2021-04-28 |
Atarga Llc |
Molécules d'anticorps se liant au composant du complément 5 et leurs utilisations
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
KR20210086623A
(ko)
|
2018-09-25 |
2021-07-08 |
하푼 테라퓨틱스, 인크. |
Ddl3 결합 단백질 및 사용 방법
|
AU2019379576A1
(en)
|
2018-11-13 |
2021-06-03 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
US20220281970A1
(en)
|
2018-12-20 |
2022-09-08 |
Novartis Ag |
Pharmaceutical Combinations
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
CN113329792B
(zh)
|
2019-02-15 |
2024-06-28 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
JPWO2020189748A1
(da)
|
2019-03-19 |
2020-09-24 |
|
|
MX2021011830A
(es)
|
2019-03-29 |
2022-01-24 |
Atarga Llc |
Anticuerpo anti fgf23.
|
KR20220066035A
(ko)
|
2019-06-21 |
2022-05-23 |
소리소 파마슈티컬스 인크. |
폴리펩타이드
|
EP3986931A1
(en)
|
2019-06-21 |
2022-04-27 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
US20230143091A1
(en)
|
2019-06-21 |
2023-05-11 |
Sorriso Pharmaceuticals, Inc. |
Compositions
|
KR20220103947A
(ko)
|
2019-10-21 |
2022-07-25 |
노파르티스 아게 |
베네토클락스 및 tim-3 억제제를 사용한 조합 요법
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
KR20220122652A
(ko)
|
2019-12-06 |
2022-09-02 |
아블린쓰 엔.브이. |
TNFα 및 IL-23을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드
|
CA3163764A1
(en)
|
2019-12-06 |
2021-06-10 |
Ablynx Nv |
Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l
|
US20210188965A1
(en)
|
2019-12-09 |
2021-06-24 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp
|
CA3165274A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのtim-3阻害剤と低メチル化剤とを含む組合せ
|
CN115298322A
(zh)
|
2020-01-17 |
2022-11-04 |
贝克顿迪金森公司 |
用于单细胞分泌组学的方法和组合物
|
JP2023527609A
(ja)
|
2020-02-21 |
2023-06-30 |
ハープーン セラピューティクス,インク. |
Flt3結合タンパク質および使用方法
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
TW202204423A
(zh)
|
2020-03-30 |
2022-02-01 |
比利時商艾伯霖克斯公司 |
用於產生和純化多價免疫球蛋白單可變域的方法
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
CA3176556A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
BR112023005273A2
(pt)
|
2020-09-25 |
2023-04-25 |
Ablynx Nv |
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l
|
EP4240765A2
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Antibody fc variants
|
WO2022104061A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
CA3201219A1
(en)
|
2020-12-04 |
2022-06-09 |
Mir Ali |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
MX2023007299A
(es)
|
2020-12-18 |
2023-07-04 |
Ablynx Nv |
Polipeptidos de reclutamiento de celulas t basados en la reactividad de tcr alfa/beta.
|
TW202239763A
(zh)
|
2020-12-18 |
2022-10-16 |
比利時商艾伯霖克斯公司 |
包含靶向IL-6和TNF-α的免疫球蛋白單可變結構域的多肽
|
TW202241947A
(zh)
|
2020-12-18 |
2022-11-01 |
比利時商艾伯霖克斯公司 |
包含靶向磷脂醯肌醇蛋白聚糖—3和t細胞受體的免疫球蛋白單可變結構域的多肽
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
IL305301A
(en)
|
2021-02-19 |
2023-10-01 |
Us Health |
Single domain antibodies neutralizing SARS CoV-2
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
CN116120449A
(zh)
*
|
2021-07-09 |
2023-05-16 |
苏州晟济药业有限公司 |
抗体以及包含其的结合剂、免疫吸附材料及其应用
|
EP4405396A2
(en)
|
2021-09-20 |
2024-07-31 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023089191A1
(en)
|
2021-11-22 |
2023-05-25 |
Ablynx N.V. |
Obtaining sequence information for target multivalent immunoglobulin single variable domains
|
CA3242445A1
(en)
|
2021-12-17 |
2023-06-22 |
Ablynx N.V. |
Polypeptides comprising immunoglobulin single variable domains targeting tcras, cd33 and cd123
|
WO2023150778A1
(en)
|
2022-02-07 |
2023-08-10 |
Visterra, Inc. |
Anti-idiotype antibody molecules and uses thereof
|
WO2023170553A1
(en)
|
2022-03-07 |
2023-09-14 |
Takeda Pharmaceutical Company Limited |
Affinity chromatographic production of clinical human igg products
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
US20240002331A1
(en)
|
2022-06-08 |
2024-01-04 |
Tidal Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
|
TW202415678A
(zh)
|
2022-06-14 |
2024-04-16 |
比利時商艾伯霖克斯公司 |
靶向t細胞受體的免疫球蛋白單可變結構域
|
WO2024017915A1
(en)
|
2022-07-18 |
2024-01-25 |
Ablynx N.V. |
Cx3cr1-binding compounds, uses thereof and related methods
|
WO2024023271A1
(en)
|
2022-07-27 |
2024-02-01 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024068944A1
(en)
|
2022-09-30 |
2024-04-04 |
Sanofi |
Anti-cd28 antibodies
|
WO2024083843A1
(en)
|
2022-10-18 |
2024-04-25 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
US20240209107A1
(en)
|
2022-12-19 |
2024-06-27 |
Sanofi |
Cd28/ox40 bispecific antibodies
|
WO2024137731A2
(en)
|
2022-12-21 |
2024-06-27 |
Genzyme Corporation |
Anti‑pd‑1×4‑1bb binding proteins
|
WO2024133935A1
(en)
|
2022-12-23 |
2024-06-27 |
Ablynx Nv |
Protein-based conjugation carriers
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
WO2024168279A2
(en)
|
2023-02-10 |
2024-08-15 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen (psma) and methods for making and using the same
|
WO2024170756A1
(en)
|
2023-02-17 |
2024-08-22 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|